Sphere Fluidics, a number one supplier of progressive microfluidics-based options for single-cell evaluation and isolation, in the present day introduced the appointment of Ed Rayner to its Board of Administrators as a Non-Govt Director. Leveraging in depth expertise in fundraising and funding inside the life sciences and know-how sectors, Ed’s appointment will strengthen the Firm’s strategic imaginative and prescient because it progresses formidable plans for future development and business success.
All through his profession, Ed has held various key analyst and portfolio administration positions at main research-led funding companies, together with AMP Capital, Alliance Bernstein, UBS Asset Administration and JP Morgan Funding Administration. He has labored throughout a broad vary of sectors, together with healthcare and know-how, along with managing fairness portfolios, working a analysis staff, and launching a small corporations fund. Extra not too long ago, Ed labored in biotech enterprise capital at Arix Bioscience and, in that position, represented the fund as an NED for numerous Life Sciences corporations, together with Pharmaxis, Depixus, and Simbec Orion Group. In his present position as a Healthcare Advisor for funding financial institution Panmure Gordon, he works with non-public Life Sciences corporations to lift capital. He has an MA in Chemistry and MSc in Administration from Oxford College, and is a Chartered Monetary Analyst.
We’re more than happy that Ed has joined the Sphere Fluidics Board. He has a wonderful worldwide funding banking background blended with expertise from main funding funds. His acumen will assist us map out our development plans, aggressive positioning and a robust exit.”
Dr. Frank F. Craig, CEO, Sphere Fluidics
Ed Rayner, Non-Govt Board Director, Sphere Fluidics, added: “I’m excited to hitch the Sphere Fluidics Board to assist the Firm because it accelerates its business roll out. The multi-disciplinary science and engineering groups have developed a ground-breaking suite of merchandise that may make an enormous distinction to the success of drug improvement programmes.”
